Explore

Trendline Trendline
ImmunityBio Faces Securities Class Action Over Misleading Statements

ImmunityBio Faces Securities Class Action Over Misleading Statements

ImmunityBio Faces Securities Class Action Over Misleading Statements
Trendline Trendline
Gossamer Bio Faces Securities Class Action After Trial Failure

Gossamer Bio Faces Securities Class Action After Trial Failure

Gossamer Bio Faces Securities Class Action After Trial Failure
Trendline Trendline
Gossamer Bio Faces Securities Class Action Following 80% Stock Drop After Trial Failure

Gossamer Bio Faces Securities Class Action Following 80% Stock Drop After Trial Failure

Gossamer Bio Faces Securities Class Action Following 80% Stock Drop After Trial Failure
Trendline Trendline
ImmunityBio Faces Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge

ImmunityBio Faces Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge

ImmunityBio Faces Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge
Trendline Trendline
Gossamer Bio Faces Securities Class Action After Phase 3 Trial Failure Causes Stock Plunge

Gossamer Bio Faces Securities Class Action After Phase 3 Trial Failure Causes Stock Plunge

Gossamer Bio Faces Securities Class Action After Phase 3 Trial Failure Causes Stock Plunge
Trendline Trendline
Faruqi Faruqi, LLP Alerts Medpace Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Medpace Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Medpace Investors of Securities Class Action Deadline
Trendline Trendline
Faruqi Faruqi Reminds Gossamer Bio Investors of Class Action Deadline

Faruqi Faruqi Reminds Gossamer Bio Investors of Class Action Deadline

Faruqi Faruqi Reminds Gossamer Bio Investors of Class Action Deadline
Trendline Trendline
ImmunityBio Faces Class Action Lawsuit Over Misleading Statements on Cancer Drug

ImmunityBio Faces Class Action Lawsuit Over Misleading Statements on Cancer Drug

ImmunityBio Faces Class Action Lawsuit Over Misleading Statements on Cancer Drug
Reuters Reuters
Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports

Lantheus weighs potential $7 billion sale after Curium's offer, Bloomberg News reports

May 22 (Reuters) - Radiopharmaceutical-focused company Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that values it at about $7 billion, Bloomberg News reported on Friday.
Trendline Trendline
Rosen Law Firm Urges Gossamer Bio Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Gossamer Bio Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Gossamer Bio Investors to Act Before Class Action Deadline
Trendline Trendline
Rosen Law Firm Urges Coty Inc. Investors to Act Before May 22 Deadline in Securities Class Action

Rosen Law Firm Urges Coty Inc. Investors to Act Before May 22 Deadline in Securities Class Action

Rosen Law Firm Urges Coty Inc. Investors to Act Before May 22 Deadline in Securities Class Action
Trendline Trendline
Rosen Law Firm Urges Upstart Holdings Investors to Join Securities Class Action

Rosen Law Firm Urges Upstart Holdings Investors to Join Securities Class Action

Rosen Law Firm Urges Upstart Holdings Investors to Join Securities Class Action